Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 2/20 | 0.48 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.48 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | PDE2A | O00408 | 2/20 | 0.33 |
| ▸ | PDE6D | O43924 | 2/20 | 0.33 |
| ▸ | PDE8A | O60658 | 2/20 | 0.33 |
| ▸ | PDE5A | O76074 | 2/20 | 0.33 |
| ▸ | PDE9A | O76083 | 2/20 | 0.33 |
| ▸ | PDE8B | O95263 | 2/20 | 0.33 |
| ▸ | PDE6A | P16499 | 2/20 | 0.33 |
| ▸ | PDE6G | P18545 | 2/20 | 0.33 |
| ▸ | PDE4A | P27815 | 2/20 | 0.33 |
| ▸ | PDE6B | P35913 | 2/20 | 0.33 |
| ▸ | PDE6C | P51160 | 2/20 | 0.33 |
| ▸ | PDE1A | P54750 | 2/20 | 0.33 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.33 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21308412 | 0.84 | DAO (0.48) | DAOATAD2HRH4PDE2APDE6D | |
| SCHEMBL17601429 | 0.76 | DAO (0.62) | DAOATAD2HRH4PDE2APDE6D | |
| SCHEMBL17614885 | 0.73 | DAO (0.47) | DAOHRH4IDH1KDM4EALDH1A1 | |
| SCHEMBL22222354 | 0.73 | DAO (0.47) | DAOHRH4IDH1KDM4EALDH1A1 | |
| SCHEMBL17614884 | 0.73 | DAO (0.47) | DAOHRH4IDH1KDM4EALDH1A1 | |
| SCHEMBL23563874 | 0.72 | P2RX7 (0.40) | PDE2AKDM4EALDH1A1KMT2A | |
| SCHEMBL23526547 | 0.72 | P2RX7 (0.40) | PDE2AKDM4EALDH1A1KMT2A | |
| SCHEMBL23526545 | 0.72 | P2RX7 (0.40) | PDE2AKDM4EALDH1A1KMT2A | |
| SCHEMBL20102638 | 0.71 | IDH1 (0.40) | DAOHRH4IDH1KMT2A | |
| SCHEMBL17616105 | 0.71 | IDH1 (0.40) | DAOHRH4IDH1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3194383-B1 | QUINOLINONE PYRIMIDINES COMPOSITIONS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS INC (US) | 2019-11-06 | — | — | EP | disclosed |
| US-20190210995-A1 | QUINOLINONE PYRIMIDINES COMPOSITIONS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. | 2019-07-11 | — | — | US | disclosed |
| US-10280150-B2 | Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors | FORMA TM2, INC. (US) | 2019-05-07 | — | — | US | disclosed |
| US-20180134682-A1 | QUINOLINONE PYRIMIDINES COMPOSITIONS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. | 2018-05-17 | — | — | US | disclosed |
| US-20180134682-A1 | QUINOLINONE PYRIMIDINES COMPOSITIONS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. | 2018-05-17 | — | — | US | disclosed |
| US-9815817-B2 | Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors | FORMA THERAPEUTICS, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-9815817-B2 | Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors | FORMA THERAPEUTICS, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20160083365-A1 | QUINOLINONE PYRIMIDINES COMPOSITIONS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. | 2016-03-24 | — | — | US | disclosed |
| WO-2016044781-A1 | QUINOLINONE PYRIMIDINES COMPOSITIONS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2016-03-24 | — | — | WO | disclosed |
| US-20160083365-A1 | QUINOLINONE PYRIMIDINES COMPOSITIONS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. | 2016-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10280150-B2 | Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors | IDH1, IDH3A, IDH3B | DAO 947/4885ATAD2 458/4885HRH4 1543/4885 |
| US-20190210995-A1 | QUINOLINONE PYRIMIDINES COMPOSITIONS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | IDH1, IDH2, IDH3A | DAO 869/4885ATAD2 784/4885HRH4 2606/4885 |
| US-20180134682-A1 | QUINOLINONE PYRIMIDINES COMPOSITIONS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | IDH1, IDH3A, IDH3B | DAO 947/4885ATAD2 458/4885HRH4 1543/4885 |
| US-20160083365-A1 | QUINOLINONE PYRIMIDINES COMPOSITIONS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | IDH1, IDH3A, IDH3B | DAO 947/4885ATAD2 458/4885HRH4 1543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.